º«¹úÂãÎè

Nada Jabado

Academic title(s): 

ProfessorÌý

MD, PhD, FRSCÌý

Nada Jabado
Contact Information
Address: 

º«¹úÂãÎè Health Centre Research Institute
1001 Boulevard, EM1 2242
Montreal, Quebec, H4A 3J1

Email address: 
nada.jabado [at] mcgill.ca
Division: 
Hematology-Oncology
Area(s): 
Epigenetics
Molecular genetics
Degree(s): 
  • MSc, Biochemistry, Université de Paris VI, Paris, France, 1992Ìý
  • ÌýDEA, Immunology, Institut Pasteur, Paris, France, 1993Ìý
  • ÌýMD, Medicine, Université de Paris VI, Inst Marie Curie, Paris, France, 1995Ìý
  • ÌýDESS, Pediatrics, Université de Paris VI, Paris, France, 1995Ìý
  • ÌýPhD, Immunology, Université de Paris VI, Inst Marie Curie, Paris, France, 1998Ìý
  • ÌýPostdoc, Biochemistry, º«¹úÂãÎè, Montreal, Quebec, Canada, 2003Ìý
Biography: 

Dr. Nada Jabado is a Professor of Pediatrics at º«¹úÂãÎè and a pediatric neuro-oncologist at the Montreal Children’s Hospital, as well as a senior scientist at the Research Institute of the º«¹úÂãÎè Health Centre. She completed her residency in pediatrics with a specialization in hemato-oncology. She also obtained a PhD in Immunology in Paris, France, followed by a postdoctoral fellowship in biochemistry at º«¹úÂãÎè. Dr. Jabado began her career as an independent investigator at º«¹úÂãÎè in 2003, pioneering a research program in pediatric brain tumours. She joined the Department of Pediatrics because “helping sick children through clinical practice and research has always been my greatest passionâ€. Dr. ´³²¹»å²¹»å´Ç’s research group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumours. More importantly, they identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1). This ground-breaking work has created a paradigm shift in cancer that has revolutionized this field, as the epigenome was a previously unsuspected hallmark of oncogenesis, thus linking development and what we now know are epigenetically-driven cancers.

Areas of expertise: 
  • Pediatric brain tumoursÌý
  • GliomasÌý
  • AstrocytomasÌý
  • EpigeneticsÌý
  • Next generation sequencingÌý
Areas of interest: 
  • Origin and pathogenesis of pediatric brain tumoursÌý
  • Role of epigenetics in development and disease
Awards, honours, and fellowships: 
  • ÌýMaude Abbott Prize, Faculty of Medicine, º«¹úÂãÎè, 2012Ìý
  • ÌýCanadian Cancer Society William E. Rawls Award, 2012Ìý
  • ÌýCanadian Gene Cure Foundation's (CGCF), Champions of Genetics Awards. Named Next generation Champion of Genetics, 2011-2013Ìý
  • ÌýAtena Prize. Awarded by the Fondazione Atena Onlus for excellence in research in Neurosciences, Rome, Italy, 2014Ìý
  • ÌýFellow, Royal Society of Canada, Academy of Science, Life Sciences Division, 2016Ìý
  • ÌýMember, Governing Council, Canadian Institute of Health Research, Health Canada, 2017Ìý
  • ÌýMember, Canadian Academy of Health Sciences, 2018Ìý
  • ÌýWomen of Action, Israel Cancer Research Fund, 2018Ìý
  • ÌýPediatric Academic Leadership, Clinician Investigator Award, Pediatric Chairs of Canada, 2019Ìý
  • ÌýCanada Research Chair in Pediatric Oncology, Tier 1, 2019Ìý
  • ÌýDr. Chew Wei Memorial Prize in Cancer Research, 2020Ìý
  • ÌýCanadian Cancer Society’s 2020 Robert L. Noble Prize, 2021
  • ÌýFédération des Médecins Spécialistes du Québec (FMSQ) Prix de la recherche 2021, co-awardee, 2021
Back to top